Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT05206357

PHASE1

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Sponsor: Genmab

View on ClinicalTrials.gov

Summary

The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). Initial treatment cures 90% - 95% of children with these malignancies, leaving a very small population of relapsed/refractory disease with a poor prognosis. The purpose of this study is to assess the safety and tolerability of epcoritamab in pediatric participants with relapsed/refractory aggressive mature B-cell neoplasms and young adult participants with Burkitt's or Burkitt-like lymphoma/leukemia. Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of relapsed/refractory aggressive mature B-cell neoplasms. Participants will receive subcutaneous (SC) of epcoritamab. Approximately 15 pediatric participants with a diagnosis of relapsed/refractory aggressive mature B-cell neoplasms and and young adult participants, ages of 18-25, with a diagnosis of Burkitt's or Burkitt-like lymphoma/leukemia will be enrolled at 50 sites globally. Participants will receive subcutaneous epcoritamab in 28-day cycles. Participants will be followed for a minimum of 3 years after enrollment. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Official title: A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms

Key Details

Gender

All

Age Range

1 Year - 25 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2022-10-04

Completion Date

2028-11

Last Updated

2025-04-08

Healthy Volunteers

Conditions

Non-hodgkin Lymphoma

Interventions

DRUG

Epcoritamab

Subcutaneous Injection (SC)

Inclusion Criteria: * Participants \>= 1 and \< 18 years old at time of primary diagnosis with Burkitt's or Burkitt-like lymphoma/leukemia, diffuse large B-cell lymphoma (DLBCL), or other aggressive mature (CD20+) B-cell lymphomas. Participants up to 25 years of age with Burkitt's or Burkitt-like lymphoma/leukemia are also eligible. * Disease pathologically confirmed (tumor tissue) by local testing. * Relapsed or primary refractory disease meeting any of the following criteria: * Progressive disease at any time during second-line chemoimmunotherapy (CIT). * Best response of stable disease (SD) after a minimum of 2 cycles of second-line CIT. * Best response of partial response (PR) after a minimum of 3 cycles of second-line CIT. * Complete Response (CR) after a minimum of 3 cycles of second-line CIT therapy but unfit or ineligible for consolidation with cell therapy. * Not in CR and unable to initiate or tolerate (i.e., must discontinue) second-line CIT. * Have received cell therapy (allogeneic or autologous transplant or chimeric antigen receptor T-cell (CAR-T) therapy) as consolidation but have not obtained or maintained a CR. * Recovery from toxic effects of prior chemoimmunotherapy. * Performance status by Lansky (\< 16 years old at evaluation) or Karnofsky (\>= 16 years old at evaluation) score \>= 50 or Eastern Cooperative Oncology Group (ECOG) score \<= 2 . * Adequate bone marrow, hepatic, and renal function. Exclusion Criteria: * Known central nervous system (CNS) involvement by lymphoma at screening as confirmed by screening magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) brain scans (participants with evidence of CNS disease only in the cerebrospinal fluid (CSF) will be eligible). * Other malignancy requiring therapy. * Currently receiving anti-cancer therapy, including chemotherapy (excluding intrathecal therapy), radiotherapy, small molecules, monoclonal antibodies, cell therapy, or other investigational agents.

Locations (41)

Lucile Packard Children's Hospital /ID# 240854

Palo Alto, California, United States

Nicklaus Children's Hospital /ID# 241174

Miami, Florida, United States

New York Medical College /ID# 239208

Valhalla, New York, United States

Levine Children's Hospital /ID# 242765

Charlotte, North Carolina, United States

Cincinnati Childrens Hospital Medical Center /ID# 239823

Cincinnati, Ohio, United States

Children's Hospital of Philadelphia - Main /ID# 239294

Philadelphia, Pennsylvania, United States

St Jude Children's Research Hospital /ID# 239184

Memphis, Tennessee, United States

University of Texas Southwestern Medical Center /ID# 240892

Dallas, Texas, United States

Children's Hospital at Westmead /ID# 240091

Westmead, New South Wales, Australia

Royal Children's Hospital /ID# 240384

Parkville, Victoria, Australia

Perth Children'S Hospital /ID# 240382

Perth, Western Australia, Australia

Universitair Ziekenhuis Leuven /ID# 242384

Leuven, Vlaams-Brabant, Belgium

Hospital for Sick Children /ID# 240767

Toronto, Ontario, Canada

CHU Sainte-Justine /ID# 240766

Montreal, Quebec, Canada

Fakultní Nemocnice Brno - Jihlavská /ID# 239956

Brno, Brno-mesto, Czechia

Duplicate_Fakultni Nemocnice v Motole /ID# 239957

Prague, Czechia

CHU Bordeaux - Hopital Pellegrin /ID# 240832

Bordeaux, Nouvelle-Aquitaine, France

CHU de Nantes, Hotel Dieu -HME /ID# 240831

Nantes, Pays de la Loire Region, France

Institut Gustave Roussy /ID# 240966

Villejuif, Val-de-Marne, France

Hospices Civils de Lyon /ID# 240834

Lyon, France

Universitaetsklinikum Erlangen /ID# 240861

Erlangen, Bavaria, Germany

Universitaetsklinikum Giessen und Marburg /ID# 240787

Marburg, Hesse, Germany

Universitaetsklinikum Muenster /ID# 239970

Münster, North Rhine-Westphalia, Germany

Schneider Children's Medical Center /ID# 240171

Petah Tikva, Central District, Israel

Rambam Health Care Campus /ID# 240037

Haifa, H_efa, Israel

The Chaim Sheba Medical Center /ID# 240670

Ramat Gan, Tel Aviv, Israel

Azienda Ospedaliero Universitaria Meyer /ID# 240049

Florence, Firenze, Italy

Fondazione IRCCS San Gerardo dei Tintori - Ospedale San Gerardo /ID# 245592

Monza, Monza E Brianza, Italy

Ospedale Pediatrico Bambino Gesù /ID# 240039

Rome, Roma, Italy

NHO Nagoya Medical Center /ID# 246680

Nagoya, Aichi-ken, Japan

Kyoto University Hospital /ID# 246907

Kyoto, Kyoto, Japan

Osaka City General Hospital /ID# 246906

Osaka, Osaka, Japan

National Cancer Center Hospital /ID# 246722

Chuo-ku, Tokyo, Japan

National Center for Child Health and Development /ID# 246658

Setagaya-ku, Tokyo, Japan

Seoul National University Hospital /ID# 239894

Seoul, Seoul Teugbyeolsi, South Korea

Samsung Medical Center /ID# 239895

Seoul, Seoul Teugbyeolsi, South Korea

Hospital Sant Joan de Deu /ID# 240719

Esplugues de Llobregat, Barcelona, Spain

Hospital Universitario Vall d'Hebron /ID# 240715

Barcelona, Spain

Hospital Infantil Universitario Nino Jesus /ID# 240717

Madrid, Spain

National Taiwan University Hospital /ID# 242890

Taipei City, Taipei, Taiwan

Koc Universitesi Hastanesi Translasyonel Tıp Arastırma Merkezi /ID# 240026

Istanbul, Turkey (Türkiye)